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ABSTRACT Ultraviolet radiation is considered the main environmental 
physical hazard to the skin. It is responsible for photoaging, sunburns, 
carcinogenesis, and photodermatoses, including drug-induced photo-
sensitivity. Drug-induced photosensitivity is an abnormal skin reaction 
either to sunlight or to artificial light. Drugs may be a cause of photoal-
lergic, phototoxic, and photoaggravated dermatitis. There are numerous 
medications that can be implicated in these types of reactions. Recently, 
non-steroidal anti-inflammatory drugs have been shown to be a com-
mon cause of photosensitivity. As both systemic and topical medica-
tions may promote photosensitive reactions, it is important to take into 
consideration the potential risk of occurrence such reactions, especially 
in people chronically exposed to ultraviolet radiation. 
KEY WORDS: photoallergic contact dermatitis, photosensitizing agents, 
phototoxic dermatitis
INTRODUCTION
Drug-induced photosensitivity is an undesirable 
effect of topically applied or systemically adminis-
trated pharmaceuticals, followed by exposition to 
sunlight, mainly ultraviolet A (UVA) or/and ultraviolet 
B (UVB) radiation as well as visible light. Such reac-
tions usually affect the skin but the eye involvement 
is also possible. There has recently been a substantial 
increase of drug-induced photoreactions as a conse-
quence of the ozone-layer depletion that allows in-
tense sunlight to reach the surface of Earth. 
Photosensitivity may be triggered by UVA and 
UVB radiation in individuals who take certain medica-
tions or who suffer from particular disorders. Photo-
sensitivity skin lesions represent 8% of all cutaneous 
adverse drug reactions (1-3).
Photosensitivity might be associated with differ-
ent mechanisms such as phototoxicity, photoallergy, 
pellagra, pseudoporphyria, lichenoid, and lupus ery-
thematosus reactions. The most common are pho-
totoxicity and photoallergy. The difference between 
them is shown in Table 1 (4-5). There are numerous 
drugs which can trigger sun-related skin reactions. 
Table 2 illustrates which drugs may induce photoal-
lergic or phototoxic reactions (6).
PhOTOTOxICITY
Phototoxicity is an abnormal chemical reaction 
induced by light. Phototoxic drugs are those which 
are able to absorb radiation. They must have a single 
or double bond or halogenated aromatic rings in the 
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molecule that determine the absorption spectrum. 
Typically wavelength causing photosensitive reac-
tions is above 310 nm.
A molecule that absorbs photons is called a chro-
mophore. The energy of the photon causes promo-
tion of the electrons from a ground state to an ex-
cited state. The so-called singlet or triplet state of the 
photosensitizer is an unstable state and exists only 
for a short time, typically up to 10-10 s for singlet and 
10-6 s for triplet states. Returning to a ground state is 
associated with a discharge of energy by radiation, 
heat emission, or a chemical reaction that results in 
the formation of a photoproduct. The energy transfer 
from excited photosensitizer to oxygen leads to the 
production of excited single oxygen atoms that can 
participate in lipid and/or protein oxidation or deoxy-
ribonucleic acid (DNA) damage. That leads to direct 
cellular damage and may induce an immunological 
inflammation (7). DNA damage may also lead to pho-
togenotoxicity that results in cancerogenesis and de-
velopment of squamous cell carcinoma.
PhOTOAllERgY
Photoallergy may be elicited by systemic as well as 
topical drugs. In both cases, photoallergic dermatitis 
is a delayed, T-cell mediated hypersensitivity reaction 
(IV type Coombs and Gell classification). Photoaller-
gic responses produced by systemically administered 
substances are much rarer than those caused by topi-
cally applied drugs. Previous sensitization to the pho-
toallergen is required. Two mechanisms of photoaller-
gic reactions have been proposed. In the first case, a 
stable photoproduct formed from the reaction of the 
drug with UV radiation serves as a hapten. A complete 
antigen is created by a combination of a hapten and 
a carrier molecule. Alternatively, a drug able to absorb 
light might be shifted to an excited, unstable state. A 
molecule reverting to its ground state results in ener-
gy release that may lead to conjugation with a carrier. 
After formation of the complete antigen, the mecha-
nism of photoallergic dermatitis is identical to the 
pathogenesis of allergic contact dermatitis. The anti-
gen is processed and presented by Langerhans cells, 
in association with human leukocyte antigen (HLA) II 
antigens. T lymphocytes are activated by Langerhans 
cells in regional lymph nodes. Skin lesions will occur 
when activated T-cells recirculate to the light-exposed 
sites and recognize the photoallergen (8).
ClINICAl fEATURES
Phototoxic reactions may occur in patients of any 
age, predominantly in women. Symptoms of photo-
toxic skin reaction resemble an exaggerated sunburn 
and are limited to the sun-exposed areas.
Phototoxicity provokes the occurrence of erythe-
ma and edema within minutes to hours. Vesiculation 
and blistering are rare. Persistent hyperpigmentation 
is also possible. The reaction is an active process of 
skin cell damage and can persist for years, long after 
the triggering factor has been removed (4).
Table 1. Phototoxic versus photoallergic reaction (4)
Phototoxicity Photoallergy
Onset of reaction minutes to hours 1-3 days
Incidence more common less common
Required exposure to agent single more than one
Mechanism reactive oxygen radicals cause 
change in skin molecules leading to 
long-term damage or cell death
UV rays activate immune system promoting activation 
of macrophages which leads to the formation of 
typical for contact dermatitis skin lesions
Immunologically mediated no yes, type IV and its subtypes (5)
Localization of lesions confined to the sun-exposed skin 
area
outbreak is not limited to the sun-exposed skin, it can 
spread to the whole body area
(less inclined to affect submental, retroauricular areas 
and upper eyelids)
Duration of the reaction active process (sometimes for years) 
even after the triggering factor was 
removed
until the trigger is removed, it can persist very 
rarely for years without further exposure to the 
photosensitizing agent
Clinical manifestation exaggerated sunburn with 
blistering, desquamation and 
hyperpigmentation
dermatitis
Concentration relation concentration related concentration not related
*UV: ultraviolet
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Photoallergic dermatitis occurs in patients of any 
age. Men are affected more commonly than women. 
Onset of these reactions is 24-72 h after exposure. 
Photoallergic dermatitis generally affects the light-
exposed areas: the face, neck, upper chest, and dor-
sum of hands. Lesions may spread to unexposed ar-
eas. Symptoms of photoallergic dermatitis are similar 
to those of contact dermatitis. Consequently, desqua-
mation and residual hyperpigmentation occur and 
can persist for more than a year. The predominant 
form of this reaction is eczematous (4).
DRUgS ASSOCIATED WITh  
PhOTOSENSITIvITY
This paper describes drug-induced photosensitiv-
ity related to: non-steroidal anti-inflammatory drugs 
(NSAIDs), cardiovascular drugs, tetracyclines, quino-
lones, voriconazole, and vemurafenib. NSAIDs are the 
most common cause of drug-induced photosensitiv-
ity. Cardiovascular drugs are one of the medications 
most widely used by elderly patients. Tetracyclines and 
quinolones are often prescribed by dermatologists 
and physicians of other specialties due to their anti-
microbial properties. Voriconazole and verumafenib 
may lead to severe photosensitivity reactions, but 
their photosensitive potential is not well-known. 
Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs are widely 
prescribed by physicians of all specialties. They have 
been found to elicit a high level of adverse photo-
sensitivity. Some NSAIDs, including ibuprofen and 
naproxen, are also available over-the-counter (9). 
Both systemic and topical administration of non-ste-
roidal anti-inflammatory drugs may promote photo-
allergic and phototoxic reactions.
NSAIDs are a heterogeneous group. Photosen-
sitivity reactions induced by the use of ketoprofen, 
naproxen, tiaprofenic acid, ibuprofen, diclofenac, pik-
etoprofen, piroxicam, celecoxib, benzydamine, and 
etofenamate have been reported (10-15). 
Table 2. Common phototoxic and photoallergic drugs (6)






Furosemide + - Unknown
Amiodarone + - UVA
Quinidine + + UVA
Thiazides + + UVA/UVB
Antibiotic Dapsone - + Unknown
Sulfonamide + + UVB
Tetracycline + - UVA/UVB
Ciprofloxacine + - UVA
Antifungal Griseofulwin + - UVA
Ketoconazole + - Unknown
DMARD Hydroxychloroquine - + Unknown
NSAID Naproxen + - UVA
Piroxicam + UVA
Tiaprofen + + UVA
Ibuprofen + - UVA
Ketoprofen + + UVA
Topical treatment
Antineoplastics 5-FU + + Unknown
Furocoumarins Psoralen + + UVA
Keratoplastics Coal tar + - UVA
PDT Pro-photosensitizer 5-Aminolevulinic acid + - UVA/visible 
spectrum
NSAID Ketoprofen + + UVA
Naproxen + + UVA
*UVA: ultraviolet A; UVB: ultraviolet B; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal anti-inflamma-
tory drugs; 5FU: Fluorouracil; PTD: photodynamic therapy
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Ketoprofen
Ketoprofen has been shown to cause most cases 
of NSAIDs-induced photosensitivity (9-10). Its admin-
istration may induce phototoxic, photoallergic, and 
phototaggravated contact dermatitis.
Ketoprofen-induced phototoxicity is dependent 
on the presence of this drug in the skin and may oc-
cur in anyone, given sufficient UV radiation. Accord-
ing to Nakajima et al. (16), ketoprofen phototoxic-
ity may involve production of oxygen free radicals, 
which are highly reactive towards proteins and lipids. 
In addition, Constanzo et al. (17) demonstrated that 
ketoprofen irritation causes the photolysis of erythro-
cyte suspension. Photolysis of erythrocytes has been 
noted as an indicator of membrane damage. The use 
of radical scavengers resulted in significant reduction 
of photosensitized lysis of red blood cells, suggesting 
the involvement of free radicals in these processes.
According to Chouini-Lalanne et al., (18) DNA may 
be another biological target of ketoprofen-induced 
phototoxicity. Ketoprofen may cause DNA cleavage in 
vitro upon irradiation. In the presence of ketoprofen, 
pyrimidine dimers are formed by an energy transfer 
mechanism involving single strand breaks.
Phototallergy due to ketoprofen is a classical de-
layed T-cell mediated hypersensitivity reaction. Keto-
profen is a propionic acid derivative, as well as a sub-
stituted benzophenone. Considering the chemical 
structure of ketoprofen, many authors (19-20), point 
out benzophenone moiety as a cause of photoaller-
gic dermatitis induced by this drug. Benzophenone 
moiety may also explain cross-reactions between ke-
toprofen and benzophenone-derived chemicals, i.e. 
benzophenone-3 (component of sunscreen creams), 
tiaprofenic acid and fenofibrate.
Cross-reactivity between ketoprofen and nonben-
zophenone-containing molecules has recently been 
also observed. Photopatch testing was positive for fen-
tichlor, tetrachlorosalicylanilide, triclosan, and hexa-
chlorophene in patients with contact photodermati-
tis to ketoprofen (21). All these molecules, including 
ketoprofen, share a benzene ring linked to an oxygen 
group, which may be involve in a cross-photosensiti-
zation phenomenon. However, a benzene ring linked 
to an oxygen group is not specific for ketoprofen.
Patients with photoallergy due to ketoprofen of-
ten present with photosensitivity to octocrylene. In 
the study by Karlsson at al. (22), all patients who had 
positive photopatch tests to ketoprofen also had pos-
itive photopatch tests to octocrylene. Patients who 
experienced photoallergic reaction to ketoprofen 
should avoid sunscreens containing benzophenone-
3 and octocrylene (23).
There are numerous case reports of photosensi-
tivity reactions in the literature, mainly to topical ke-
toprofen.
Matthieu et al. (24) performed patch tests and 
photopatch tests in 20 patients suspected of keto-
profen-induced dermatitis. Photoallergic contact der-
matitis to ketoprofen was confirmed in 17 patients. 
Patch and photopatch tests demonstrated a contact 
allergy in 1 patient and a photoaggravated contact 
allergy in 2 patients. Severe skin lesions requiring sys-
temic corticotherapy were present in 47% of patients. 
26% of patients required hospitalization. Prolonged 
photosensitivity was observed in one patient. 
Caterina et al. (25) reported 2 cases of photoder-
matitis due to systemic ketoprofen in patients with 
previous reactions to topical application of this drug. 
Both patients developed eczematous skin lesions 
within photoexposed areas of a body after oral ad-
ministration of ketoprofen. These cases highlight a 
possibility of photosensitivity reactions due to oral 
ketoprofen in patients with a history of photocontact 
dermatitis after previous topical application of this 
medicine.
There were 3 cases of photoallergic contact der-
matitis after topical use of ketoprofen reported in pa-
tients diagnosed at the Department of Dermatology 
of the Poznan University of Medical Sciences. All pa-
tients experienced eczematous skin lesions. In 2 pa-
tients skin lesions had a bullous manifestation. In all 
cases, the skin lesions were restricted to the skin area 
of drug application. The delay between the applica-
tion of ketoprofen and the reaction was between 2 
and 60 days. One patient presented with a recurrence 
of the photosensitivity phenomenon after 1 year 
since the previous reaction (26).
Piroxicam
Piroxicam has been known as an important photo-
sensitizer since 1983, when Fjellner (27) reported the 
first case of piroxicam-induced photosensitivity. Fjell-
ner observed an erythematous-bullous eruption on 
light-exposed skin areas in a woman who was treated 
with systemic piroxicam due to rheumatoid arthritis. 
Photopatch tests were performed and showed a posi-
tive reaction to piroxicam. There are numerous case 
reports in the literature of photodermatitis caused by 
both oral and systemic piroxicam (9,28).
Photosensitivity induced by piroxicam may result 
in both phototoxic and photoallergic reactions and 
can be due to topical or systemic administration (29). 
Piroxicam is widely used in treatment of rheumato-
logic diseases, and 1-3% of patients taking this drug 
experience adverse cutaneous reactions (28). Upon 
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low UVA irradiation, a photoproduct of piroxicam 
is formed which is chemically similar to thiosalicylic 
acid (moiety of thimerosal). This mechanism may be 
responsible for cross-reactivity between piroxicam, 
thiosalicylic acid, and thimerosal (30). Most data do 
not support cross-reactivity between different oxi-
cams (10,31), although a case photodermatitis elic-
ited by piroxicam with a positive photopatch test to 
other oxicams has been reported (29).
Benzydamine
Benzydamine is an indazole non-steroidal anti-in-
flammatory drug. It is available in Poland as a vaginal 
solution, mouth aerosol, and throat lozenges. Pho-
tosensitivity from benzydamine may be underdiag-
nosed and has been occasionally described.
Benzydamine has phototoxic and photoallergic 
properties (32). Used as a mouth aerosol or solution, 
it can induce cheilitis and chin dermatitis as a mani-
festation of photoallergy.
Canelas et al. (33) investigated photocontact al-
lergy to benzydamine in a group of 74 patients They 
performed photopatch testes with an extended series 
of allergens including benzydamine. In 10 patients a 
positive photopatch test to benzydamine was detect-
ed. Nine patients presented with lower lip cheilitis 
and one lichenified eczema on photoexposed areas 
(face, neck, upper chest, forearms, dorsum of hands).
Another description of photocontact allergy 
caused by benzydamine was published by Elgezua et 
al. (34). They reported a case of a photoallergic hand 
eczema due to benzydamine present in a gyneco-
logical washing solution. Eczema presented on the 
dorsum of both hands. The rest of the skin, including 
external genital organs, was unaffected. The diagno-
sis was confirmed using photopatch tests.
Diclofenac
Although diclofenac is a well-known possible pho-
tosensitizer, there are only a few reports of it causing 
photosensitivity reactions.
Portuguese researchers performed photopatch 
tests in 30 patients with suspected photoaggravated 
facial dermatitis or systemic photosensitivity. One 
patient had a positive reaction to diclofenac. Diclofe-
nac-induced photoallergy was attributed to systemic 
photosensitivity (31).
Kowalzick et al. (35) reported a case of photoal-
lergic contact dermatitis from topical diclofenac in a 
77-year old female patient who was treated with 3% 
topical diclofenac due to actinic keratosis. The patient 
developed exsudative, itching erythema on the right 
cheek where the topical diclofenac was applied. She 
presented with positive patch and photopatch test 
results.
One case of photoallergic contact dermatitis 
due to topical use of diclofenac was reported in a 
29-year-old male patient who was diagnosed at the 
Department of Dermatology of the Poznan Univer-
sity of Medical Sciences. The patient presented with 
eczematous skin lesions on the right foot 7 days after 
application of the drug (26).
Cardiovascular and diuretic agents
Amiodarone
Amiodarone is a systemic antidysrhythmic drug 
that may provoke a wide range of photosensitive re-
actions. The phenomenon is UVA and visible light de-
pendent and may be provoked by glass-transmitted 
light even on cloudy days or during winter time. Dur-
ing sun exposure an immediate erythema, stinging, 
or burning may occur. The agent is prone to induc-
ing exaggerated sunburn, pseudoporphyria, hyper-
pigmentation, and delayed erythema. Urticaria and 
edema may occur with higher doses. A minority of 
patients may present an abnormal golden-brown or 
unsightly grey pigmentation that does not disappear 
immediately after drug cessation and may persist for 
months along with photosensitivity. When amioda-
rone is a drug of last resort, dosage reduction com-
bined with photoprotection is the only possibility of 
management (3).
Statins
Statins are one of the most frequently adminis-
tered lipid-lowering agents worldwide (36). Cutane-
ous reactions have been reported among the mul-
tiple adverse effects of these 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase inhibitors, 
mainly due to photosensitivity. Photophysical and 
photochemical results indicate that singlet oxygen 
formation generated by the phenanthrene-like pho-
toproduct of atorvastatin can induce phototoxic re-
action (36). UVB-mediated phototoxicity due to ator-
vastin was reported (37). Rosuvastatin was described 
as a potential sensitizer through its dihydrophenan-
threne-like compound (38). 
Fluvastatin has been proven to act as a phototoxic 
agent after UVA irradiation through its benzocarba-
zole-like photoproduct. It has been reported that the 
phototoxic compound of fluvastatin mainly caused 
necrosis of the analyzed keratynocites (39). 
Simvastatin and pravastatin are known causes of 
photoinduced erythema multiforme (40).
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The literature of case reports of phototoxic and 
photoallergic skin reactions of HMG-CoA reductase 
inhibitors is scarce. Thus it may appear that photo-
sensitivity is not a common clinical problem in this 
group of drugs.  
Thiazides and Furosemide
Thiazide diuretics may provoke exaggerated sun-
burn, which if recurrent, may induce chronic actinic 
dermatitis. Some patients present lupus and lichen 
planus-like eruptions. The photochemical activity is 
due to a chlorine substituent which is present in the 
structure of thiazides and furosemide. The UV disso-
ciation of the chlorine substituent leads to reactions 
with lipids, proteins, and DNA (7). Photosensitivity is 
idiosyncratic and rare. The management involves a 
substitution of the thiazide with a relatively less pho-
toactive loop diuretic (2).
Qunidine
The photosensitive reaction provoked by quni-
dine sulphate has been known since 1942. The mech-
anism is a type-IV allergic reaction (2).
Antibacterial drugs
Tetracyclines 
Tetracyclines are one of the most frequent photo-
sensitizing agents among antibacterial drugs. There 
is a significant difference in the phototoxic index 
among the derivatives.
Demethylchlortetracycline and doxycycline have 
the highest phototoxic potential; tetracycline and 
oxytetracycline are less photoactive. Minocycline and 
lymecycline have the lowest index of phototoxicity 
among tetracyclines (41-43). Layton et al. (44) report-
ed that the phototoxic phenomenon of doxycycline 
is dose dependent (Table 3).
The typical clinical manifestation of phototoxic 
reaction to tetracycline is sunburn, which may be as-
sociated with papular eruption or blistering (43). Tet-
racycline-induced photoonycholysis may also occur, 
usually at least 2 weeks after drug administration (45).
Yap et al. (46) reported a case of solar utricaria 
caused by tetracycline. A 28-year-old woman treated 
with oral tetracycline developed macular erythema 
and pruritus. Skin lesions were restricted to the sun-
exposed area of the body. Photopatch testing demon-
strated urticarial reaction within 15 minutes. After ces-
sation of tetracycline, phototesting was negative.
Quinolones
Quinolones are broad spectrum antibacterial 
drugs which may induce photosensitization reactions 
of a varying degree of severity. There are four genera-
tions of quinolones. Presently, the therapeutic use of 
first generation quinolones is very limited in Europe, 
although some of them are still marketed in several 
countries, for instance nalidixic acid and pipemidic 
acid (47). There are many reports proving the photo-
toxicity potential of representatives of all quinolone 
generations, for example nalidixic acid, pipemidic 
acid, ciprofloxacin, fleroxacin, norfloxacin, moxifloxa-
cin, lomefloxacin, ofloxacin, and rufloxacin (48).
Quinolones mostly cause phototoxic reactions, al-
though there are also some reports of photoallergy. 
There has been evidence of the photoallergic poten-
tial of lomefloxacin and nalidixic acid (49,50).
The study of Wagai et al. and Marutani et al. dem-
onstrate that lomefloxacin is the most phototoxic 
of fluoroquinolones. In the first study its photosen-
sitizing action was stronger than nalidixic acid. Fur-
thermore, empirical studies have suggested that 
moxifloxacin may be a mild photosensitizer. Methoxy 
group substitution may reduce the photosensitizing 
activity of moxifloxacin (48,51,52).
Novel drugs
Several recently produced drugs have photosen-
sitising potential. Such drugs include antifungal vori-
conazole (53,54) or anticancer drugs eg. vemurafenib. 
Voriconazole, which is a triazol antifungal agent and 
is widely used as a prophylaxis in patients after trans-
plantations, exhibits its phototoxic potential in par-
ticular during long-term treatment. This agent may 
be associated with chronic phototoxicity, accelerated 
Table 4. Classification criteria for photopatch test 
reaction (54)
Point Scale Skin lesion type
0 No reaction
1 Erythema
2 Erythema and dermal infiltrate
3 Erythema and papulovesicles
4 Erythema and blisters or erosion
Table 3. Dose-dependent phototoxicity to doxy-
cycline (44)
Dose of doxycycline 
(mg/day)
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photo-aging, and, most likely, development of squa-
mous cell carcinoma. Vemurafenib is an orally admin-
istered inhibitor of BRAF kinase used in the treatment 
of late-stage melanoma (55,56). During the treatment, 
patients frequently experience immediate phototoxic 
reactions among othercutaneous side effects. Stud-
ies have shown that this reaction is UVA dependent 
and probably related to decreased vitamin PP level 
and increased porphyrins levels (57). It is essential 
when developing new drugs to predict the potential 
for phototoxicity of its compounds. Over the past few 
years some effective methodologies have led to the 
formation of some regulatory guidelines of drug pho-
tosafety (58).
Over-the-counter photosensitisers
Cosmetics such as sunscreens or anti-aging prod-
ucts that contain benzophenones or octocrylenes 
may also be a cause of photosensitive reactions 
(58,59).
Some photosensitizers such as ibuprofen, naprox-
en, diclofenac, and some plant extracts eg. Hypericum 
perforatum are available over-the-counter in Poland.
Patients are seldom aware of the potential risk of 
an adverse skin reaction and use medications with-
out consulting their physician. Thus, it is important to 
educate and increase awareness of possible photo-
sensitivity. 
Photopatch testing
Phototesting is a helpful tool in diagnosing drug-
induced photosensitivity. Ketoprofen, etofenamate, 
piroxicam, and benzydamine are the only NSAIDs 
included in the standard photopatch test series (60). 
This procedure should not be performed while der-
matitis is active. Photopatch testing should be under-
taken on skin that has not been affected for the last 2 
weeks to avoid the effects of the so-called the “angry 
back” syndrome. The best choice for the testing area 
is the skin of the upper back, avoiding the paraver-
tebral area (61). Patch series have to be applied in a 
duplicate set on either side of the vertebrae. One set 
is fixed to the skin for 24 hours. After 24 hours it is re-
moved and irradiated with UVA (psoralen combined 
with ultraviolet A (PUVA) fluorescent lamp of broad 
spectrum) of 5 J cm2. The control non-irradiated set 
can be fixed for either 24 or 48 hours, after which is 
removed. The irradiated test site is read before, imme-
diately, and 48, 72, and 96 hours after irradiation. The 
un-irradiated test site has to be evaluated after patch 
test removal as well as after 48, 72, and 96 hours. Ery-
thema, dermal infiltrate, papulovesicles, blisters, and 
erosion indicate a positive reaction (Table 4) (62). A 
positive response at an irradiated site and negative at 
a control site is interpreted as a positive photopatch 
test reaction. Positive reaction at both sites is regard-
ed as a contact reaction that may be aggravated by 
the UV light (Table 5) (61,62).
CONClUSION
Drug-induced photosensitivity may cause seri-
ous diagnostic difficulties, especially when it comes 
to systemic medications. Knowledge of drugs prone 
to inducing such an adverse reaction is crucial when 
choosing the right treatment modality. It is important 
to establish the potential risk of causing a photosen-
sitive reaction before beginning phototherapy or la-
ser therapy, especially in patients chronically exposed 
to sunlight due to professional reasons.
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